The Liquid Biopsy Summit Brochure 2016

LIQUIDBIOPSYSUMMIT.COM

Keynote SpeakersEllen M. Beasley, Ph.D., Senior Vice President, Product & Services Research & Development, Business & Product Development,

Genomic Health, Inc.

Steven A. Soper, Ph.D., Professor, Biomedical Engineering & Chemistry; Associate Editor, Analyst; Director, Center for BioModular Multiscale

Systems, University of North Carolina

Muneesh Tewari, M.D., Ph.D., Associate Professor, Internal Medicine and Biomedical Engineering & Ray and Ruth Anderson-Laurence M. Sprague

Memorial Research Professor, University of Michigan Health System

Symposium June 22Circulating Markers in Cancer: Tools for Identification, Evaluation and Translation

Dinner Short Course June 23Molecular Beacons; Stellaris FISH Probes; and SuperSelective PCR Primers for Liquid Biopsies

Conference Sessions June 22 - 24Oncology: Liquid Biopsies Are Advancing into the ClinicTools that Capture, Amplify and Analyze Minute Amounts of Nucleic AcidsMoving Beyond Cancer: Tackling Other TargetsDetecting the Role of Extracellular RNAs in Health and Disease

LIQUID BIOPSYSUMMIT

THEJUNE 22 - 24, 2016HOTEL KABUKI | SAN FRANCISCO, CALIFORNIA

Refining Circulating Cell-Free Tools and Technologies for Translational Research

final agenda

Register by March 18

Save up to $400

CORPORATE SUPPORT SPONSOR

CORPORATE SPONSOR

Join your peers and colleagues in San Francisco to gain insight and perspective on why molecular liquid biopsies have the potential to become a fulcrum in the future of precision medicine.

This is an unprecedented time in biomolecular medicine. Recent scientific findings have determined biofluids consist of circulating cell-free (cf)DNA and extracellular (ex)RNA from multiple tissues within the body. In addition, the rapid development of highly sensitive and accurate next-generation sequencing (NGS) technologies has empowered researchers to analyze the role of these biomolecules in health, disease and treatment response. However, there remains considerable insecurity associated with biofluid-based DNA/RNA analytical methods which must be solved before liquid biopsies can be implemented for broader routine applications.

2 LIQUIDBIOPSYSUMMIT.COM

Present Your Research Poster and Save $50!Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by May 13, 2016

Reasons you should present your research poster at this conference:• Your poster will be seen by

our international delegation, representing leaders from top pharmaceutical, biotech, academic and government institutions

• Receive $50 off your registration • Your poster abstract will be published

in our conference materials

molecular beacons; stellaris fish probes; and superselective pcr primers for liquid biopsies

dinner short course*

THURSDAY, JUNE 23 | 5:45-8:45 PM

SC1: Molecular Beacons;Stellaris FISH Probes; and SuperSelective PCR Primers for Liquid BiopsiesInstructors:Fred Russell Kramer, Ph.D., Professor, Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers UniversitySanjay Tyagi, Ph.D., Professor, Medicine, Public Health Research Institute, New Jersey Medical School, Rutgers University

Section 1: Finicky and Sloppy Molecular Beacons

Section 2: Imaging Single mRNA Molecules in Living and Fixed Cells

Section 3: Multiplex Real-Time PCR Assays that Assess the Abundance of Extremely Rare Mutations Associated with Cancer

Please visit the conference website for a complete syllabus.* Separate registration required

CORPORATE SUPPORT SPONSORCORPORATE SPONSOR

EVENT FEATURESThe Liquid Biopsy Summit is uniquely designed to provide up-to-date coverage for this rapidly evolving field through:

Networking

• Breakout Discussion Groups• Reception and Refreshment Breaks

One-on-One Discussions

• Poster Sessions• Q&A following Presentations• Solution Providers

In-Depth Coverage

• Symposium on current technologies for CTCs and (cf)DNA

• Short Course on PCR: Probes, Primers, and Beacons • Panel Discussion on current challenges and future

opportunities • Identifying biofluid molecular markers (cf)DNA and

(ex)RNA from tissue• Latest research from academic, biotech, and

established diagnostic companies • Providing faster, cheaper, and less invasive biopsies• Developing clinically actionable tests• Expanding molecular targets and indications• Combining liquid biopsies with personalized therapies

Unique Japantown Location

• Convenient location near many San Francisco attractions

• Rich in Culture and Luxury

#LBS16STAY CONNECTED

LIQUIDBIOPSYSUMMIT.COM 3

WEDNESDAY, JUNE 22

7:30 am Symposium Registration and Morning Coffee

From CTCs to New Diagnostics

8:30 Organizer’s Opening RemarksMary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute

8:35 Chairperson’s Opening RemarksLidia C. Sambucetti, Ph.D., Senior Director, Cancer Research Technologies, SRI International Biosciences Division

»8:45 KEYNOTE PRESENTATION: New Tools for the Isolation of Circulating Markers: Microfluidic Systems for the Analysis of Circulating Cells, Cell-Free DNA and Exosomes

Steven A. Soper, Ph.D., Professor, Biomedical Engineering & Chemistry; Associate Editor, Analyst; Director, Center for BioModular Multiscale Systems, University of North Carolina Liquid biopsies are generating interest within the biomedical community due to the simplicity for securing important markers to realize precision medicine. These circulating markers consist of whole cells such as CTCs, molecules such as cell-free DNA and nanovesicles such as exosomes. We are developing microfluidic systems that can process whole blood directly and select all three of these markers from a single blood sample. The devices can not only collect the markers from blood samples, but also perform molecular analysis on their cargo.

9:15 Optical Technologies for CTC AnalysisGregory Faris, Ph.D., Program Manager, Optical Systems, Discovery Technologies, SRI InternationalThis talk describes two technologies for CTC analysis. The first is a non-enrichment method for selection of CTCs using optical imaging. The second method uses laser heating for multiplexed in situ PCR and RT-PCR in nanoliter droplets without removing cells.

9:45 Trends in Automating CTC Capture: Progress towards a Simple and Inexpensive AssaySiddarth Rawal, M.D., COO, Circulogix Inc.; Clinical Research Associate, Miller School of Medicine, University of MiamiCirculating tumor cells (CTC) have been regarded as important biomarkers for cancer prognosis, monitoring treatment response and companion diagnostics to assess efficacy of novel targeted drugs in development. However, the effective and complete enrichment of these rare events from whole blood remains a non-trivial, manual-intensive and expensive endeavor. Reliable automated technologies are needed to provide a consistent and easy workflow to generate exciting discoveries.

10:15 Networking Coffee Break

10:45 Circulating Tumor Cells in the Peripheral Blood Decrease in Numbers with Treatment in Patients with Various CarcinomasRebecca (Becky) Suttmann, MS, Senior Scientific Researcher, Oncology Biomarker Development, Genentech, Inc. We summarize findings of CTC enumeration utilizing the CellSearch® platform for isolating and enumerating cells from nearly 10,000 fresh whole-blood samples from cancer patients enrolled in 20 clinical trials conducted by Genentech over four years. Incidence and changes in CTC number and presence of targeted markers were measured. Evaluation of numerous patient samples across multiple indications has provided an opportunity to assess utility of CTC analysis on the CellSearch® platform in the context of clinical drug development.

11:15 Microfluidics-Based Biomarker Isolation and Analysis for Cancer Detection from Blood SamplesRolf Muller, Ph.D., CEO, BioFluidica, Inc.BioFluidica has developed a comprehensive platform technology to isolate and detect rare biomarkers in blood samples. The technology allows large-volume, whole-blood processing with high biomarker recovery and purity.

The technology is based on microfluidic isolation technology and has been clinically validated for six different cancer types. We focus on the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood.

11:45 Sponsored Presentation (Opportunity Available)

12:15 pm Session Break

12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:00 Session Break

Big Data and Applications of Analysis of ctDNA2:00 Chairperson’s RemarksLidia C. Sambucetti, Ph.D., Senior Director, Cancer Research Technologies, SRI International Biosciences Division

2:05 Studying the Tumor Microenvironment with Big DataDvir Aran, Ph.D., Research Scientist, Atul Butte Laboratory, Institute for Computational Health Sciences, University of California, San FranciscoPublic genomic data now offer the opportunity for bioinformaticians to study the tumor microenvironment. I present a systematic pan-cancer analysis of tumor purity, which demonstrates how “purity” significantly biases genomic analyses. However, this also allows new opportunities to study the crosstalk of the microenvironment with the cancer. I conclude with our recent advances to dissect the microenvironment further.

2:35 Monitoring Circulating Tumor DNA to Assess Chemotherapeutic EffectivenessTimothy Butler, Research Scientist, Paul Spellman Laboratory, Knight Cancer Institute, Oregon Health & Science UniversityCirculating-tumor DNA (ctDNA) analysis has the potential to improve how we monitor and treat patients with cancer. In this study we utilize a hybrid-capture approach to sensitively monitor the ctDNA of breast cancer patients before, during, and after undergoing neoadjuvant chemotherapy. Our findings offer interesting insights into patient responses to neoadjuvant chemotherapy, and may improve prognostic and treatment decisions following therapy.


3:20 Networking Refreshment Break

3:45 Liquid Biopsy in Prostate CancerJohn S. Witte, Ph.D., Professor and Head, Division of Genetic and Cancer Epidemiology; Associate Director, Institute for Human Genetics; Co-Leader, Cancer Center Program in Cancer Genetics, University of California, San Francisco

4:15 Liquid Biopsies – Pushing the EnvelopePamela Paris, Ph.D., Professor of Urology, Department of Urology, University of California, San Francisco

4:45 PANEL DISCUSSION: Current and Future Applications of Liquid Biopsies in CancerAll agree CTCs and ctDNA are prognostic and predictive biomarkers for cancer. However, different approaches for CTCs/ctDNA detection and analysis to identify these tumor cell subpopulations need technical standardization before their clinical validity and biological specificity may be adequately investigated. Join these panelists as they discuss the current challenges and future opportunities for liquid biopsies.Panelists:Ellen M. Beasley, Ph.D., Genomic Health, Inc.Geoff Otto, Ph.D., Foundation MedicineSteven A. Soper, Ph.D., University of North CarolinaRebecca (Becky) Suttmann, MS, Genentech, Inc.John S. Witte, Ph.D., University of California, San Francisco

5:30 Welcome Reception in the Exhibit Hall with Poster Viewing

6:30 Close of Day

circulating Markers in cancer:Tools for Identification, Evaluation and Translation

symposium


WEDNESDAY, JUNE 22

3:45 pm Main Conference Registration

4:45 PANEL DISCUSSION: Current and Future Applications of Liquid Biopsies in CancerAll agree CTCs and ctDNA are prognostic and predictive biomarkers for cancer. However, different approaches for CTCs/ctDNA detection and analysis to identify these tumor cell subpopulations need technical standardization before their clinical validity and biological specificity may be adequately investigated. Join these panelists as they discuss the current challenges and future opportunities for liquid biopsies.Panelists:Ellen M. Beasley, Ph.D., Genomic Health, Inc.Geoff Otto, Ph.D., Foundation MedicineSteven A. Soper, Ph.D., University of North CarolinaRebecca (Becky) Suttmann, MS, Genentech, Inc. John S. Witte, Ph.D., University of California, San Francisco

5:30 Welcome Reception in the Exhibit Hall with Poster Viewing

6:30 Close of Day

THURSDAY, JUNE 23

8:00 am Morning Coffee

Oncology: Liquid Biopsies Are Advancing into the Clinic8:30 Organizer’s Opening RemarksMary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute

8:35 Chairperson’s Opening RemarksJamie Platt, Ph.D., MB(ASCP), Molecular Pathology Laboratory Network

»8:45 KEYNOTE PRESENTATION: Liquid Biopsies in Cancer Disease Management

Ellen M. Beasley, Ph.D., Senior Vice President, Product & Services Research & Development, Business & Product Development, Genomic Health, Inc.Liquid biopsies can be used to monitor tumor dynamics including recurrence, or to profile individual genetic and genomic markers that are informative of treatment options. Together, these complementary approaches provide precision solutions to help manage disease along the patient cancer journey. These also call for different development, analytical and clinical validation strategies, as well as demonstration of clinical utility.

9:30 Circulating RNAs as Noninvasive Biomarkers in Colorectal CancerAjay Goel, Ph.D., Investigator/Professor & Director, Center for Gastrointestinal Research; Director, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical CenterGiven their cancer-specific pattern of expression, remarkable stability and presence in blood and other body fluids, noncoding RNAs (ncRNAs) are considered to be highly promising “liquid biopsy” cancer biomarkers. Accumulating evidence firmly supports the existence of unique “ncRNA signatures” that can not only facilitate earlier detection of the tumor, but can also assist in predicting disease recurrence and therapeutic outcome to current treatment regimens.

10:00 Accessing Genetic Information with Liquid BiopsiesJian-Bing Fan, Ph.D., CEO, AnchorDx Corp.The molecular liquid biopsies approach provides non-invasive access to genetic information – somatic mutations, epigenetic changes, and differential expression – about the physiological conditions of our body and diseases. With the rapid development of highly sensitive and accurate technologies such as next-generation sequencing, it is now possible to reliably analyze CTCs and circulating nucleic acids in a clinic setting, which opens a valuable avenue for future genetic studies and human disease diagnosis.

10:30 Coffee Break in the Exhibit Hall with Poster Viewing

11:00 Analytic Validation of an NGS-Based Clinical ctDNA AssayGeoff Otto, Ph.D., Senior Director, Molecular Biology & Sequencing, Foundation MedicineProfiling circulating tumor DNA (ctDNA) for the genomic alterations (GA) driving oncogenesis promises to provide insight into cancer biology, inform therapy selection when conventional biopsies are unobtainable and enable monitoring of response to therapy. A clinical, NGS-based ctDNA assay was developed, highly accurate detection of GA was analytically validated and clinical utility investigated from patient-matched FFPE and blood samples across lung, breast and colon cancer at different disease stages.

11:30 Nucleosome Footprints in Cell-Free DNA Are Evidence of Its Tissues of OriginAndrew Hill, Graduate Research Fellow, Jay Shendure Laboratory, Genome Sciences, University of WashingtonNucleosome positioning varies across cell types. Some proportion of cell-free DNA (cfDNA) is protected by nucleosomes, which in principle could allow detection of cell types contributing to cfDNA. We infer nucleosome positioning in cfDNA to identify abnormal contributions in pathologies such as cancer. Because this method does not rely on genetic differences between healthy and pathological contributions, it could potentially broaden the scope of cfDNA-based monitoring and diagnostics.

12:00 pm Presentation to be Announced Sponsored by


12:30 Session Break


1:15 Session Break

Tools that Capture, Amplify and Analyze Minute Amounts of Nucleic Acids

2:00 Chairperson’s RemarksEllen M. Beasley, Ph.D., Genomic Health, Inc.

2:05 Nanocarbon-Coated Porous Anodic Alumina for Biological ApplicationsSteven Prawer, Ph.D., D.Sc., Professor of Physics, School of Physics, University of MelbourneHere we demonstrate a new broad-range sensor platform for ultrasensitive and selective detection of circulating DNA down to the single-molecule level. The biosensor is based on a chemically functionalized nanoporous diamond-like carbon (DLC)-coated alumina membrane. The few nanometer-thick, yet perfect and continuous DLC coating confers the chemical stability and biocompatibility of the sensor, allowing its direct application in biological conditions.

liquid biopsy summitTHEConference Agenda


2:35 T Oligo-Primed Polymerase Chain Reaction (TOP-PCR): A Robust Method for the Amplification of Minute Amount of DNA Fragments from Body FluidsKuo Ping Chiu, Ph.D., Associate Research Fellow, Genomics Research Center, Academia SinicaWe have developed T oligo-primed PCR (TOP-PCR) for comprehensive amplification of minute DNA fragments. TOP-PCR adopts homogeneous adaptor (generated by P oligo and T oligo) for efficient ligation to A-tailed DNA, followed by PCR amplification primed by T oligo. We demonstrate that TOP-PCR maintains the size profile of the DNA sample and is a superior method for recovering minute DNA in body fluids. It maximizes the resolution of Illumina sequencing.


3:20 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 Sample Prep in Genetic Assay DevelopmentToumy Guettouche, Ph.D., Director, Early Development & Genetics Assay Development, Sequencing Unit, Roche Molecular Systems

4:30 Sample Prep in Liquid Biopsy; Can We Always Win the Lottery?Jamie Platt, Ph.D., MB(ASCP), Vice President, Genomic Solutions, Molecular Pathology Laboratory NetworkThe introduction of NGS has enabled some remarkable applications which allow for less invasive specimen acquisition, and improved sensitivity and specificity. Liquid biopsy is one application that holds enormous promise as a tool for monitoring therapeutic response, detect residual disease, and even provide an earlier diagnosis. However, one fact remains: you can’t detect what you haven’t sampled. The key issues and opportunities for liquid biopsy sample prep will be discussed.

5:00 Next-Generation Liquid Biopsy: Tumor Monitoring from Droplet Volumes of BloodChen-Hsiung Yeh, Ph.D., CSO, Circulogene TheranosticsCirculating cell-free DNA (cfDNA) can provide a global longitudinal picture of tumor heterogeneity. Large sample volume, low yield, and labor intensiveness are major obstacles for clinical application of cfDNA-based testing. Our proprietary cfDNA sample preparation breakthrough enables clinicians to work with a sample volume as small as 20 microliters (via a finger prick), which can further expedite clinical decision-making and identify targeted therapies for eligible patients in a time- and cost-efficient manner.

5:30 Close of Day and Short Course Registration

5:45-8:45 Dinner Short Course*SC1: Molecular Beacons; Stellaris FISH Probes; and SuperSelective PCR Primers for Liquid Biopsies*Separate registration required. See page 2 for details.

FRIDAY, JUNE 24

7:30 am BREAKFAST BREAKOUT DISCUSSION GROUPSChew over breakfast and provocative discussion topics with your peers. These are moderated discussions with brainstorming and interactive problem solving, allowing conference participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic.

Standards of Evidence, Methods and Materials to Accelerate Liquid Biopsy Development and AdoptionModerator: Ellen M. Beasley, Ph.D., Genomic Health, Inc.

Taking ctDNA to the Clinic: Best Applications of Liquid Biopsies to Improve Cancer TreatmentModerator: Timothy Butler, Oregon Health & Science University

Use of Systems or Computational Biology to Decipher the Molecular Information that Arises from High-Throughput Liquid Biopsies from the Plasma Moderator: Stephen Y. Chan, M.D., Ph.D., University of Pittsburgh Medical Center

NGS for Clinical Infectious Disease DiagnosticsModerator: Charles Chiu, M.D., Ph.D., University of California, San Francisco

Nanoscience in the Service of Biological Technologies Moderator: Steven Prawer, Ph.D., D.Sc., University of Melbourne

Additional Breakout Discussion Groups to be Announced

Moving Beyond Cancer: Tackling Other Targets

8:45 Chairperson’s Opening RemarksCharles Chiu, M.D., Ph.D., University of California, San Francisco

8:50 Cell-Free DNA in Transplant MedicineKiran K. Khush, M.D., MAS, FACC, Associate Professor, Medicine, Division of Cardiovascular Medicine, Stanford University School of MedicineThis talk reviews clinical applications of cell-free DNA testing in the field of solid organ transplantation. Topics covered include (1) monitoring for acute rejection, with illustrative cases from heart and lung transplantation, (2) monitoring of the transplant recipients’ virome, and how it changes with introduction and weaning of immunosuppression, and (3) non-biased detection of disease-causing pathogens in transplant recipients.

9:20 Liquid Biopsy of the HIV Latent Reservoir in Patients on Anti-Retroviral TherapiesXiaohe Liu, Ph.D., Senior Scientist & Co-Leader, Rare Cell Technology Program, Biosciences Division, SRI InternationalA major hurdle in HIV eradication research is the lack of robust assays to characterize the reservoir cells that harbor HIV in the presence of anti-retroviral therapy (ART). We applied FAST (Fiber-optic Array Scanning Technology) to detect and characterize rare cells that express HIV proteins in peripheral blood of patients on ART. Our data suggest that FAST may be a new, important method to identify and measure replication competent proviruses.

9:50 Metagenomic Next-Generation Sequencing for Diagnosis of Infectious Diseases from Cell-Free FluidsCharles Chiu, M.D., Ph.D., Associate Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine, University of California, San FranciscoMetagenomic next-generation sequencing (mNGS) is a powerful approach to the diagnosis of infectious diseases, as it does not rely on targeted primers or probes. A single sequencing test is able to identify all viruses, bacteria, fungi, and parasites in clinical samples. Here we describe implementation of a clinically validated mNGS assay from cerebrospinal fluid to diagnose meningitis and encephalitis in critically ill hospitalized patients.


10:35 Coffee Break in the Exhibit Hall with Poster Viewing

11:10 Looking for the Free Agents in Blood: High-Sensitivity RNA-Seq Approaches for Detecting Infectious Agents in Liquid BiopsiesAndrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University

11:40 Using Immune Profiles to Categorize Neurological DiseaseNancy Monson, Ph.D., Associate Professor, Department of Neurology and Neurotherapeutics & Department of Immunology, University of Texas Southwestern Medical CenterCerebrospinal fluid (CSF) samples have been a useful tool in the diagnosis of neurological diseases involving the central nervous system (CNS). Our laboratory has focused on finding new ways to use CSF as a diagnostic tool for multiple sclerosis, an autoimmune disease of the CNS. We discovered that antibody genetics of CSF-derived B cells can be used to identify patients who have MS and patients who will develop MS in the future with 84-92% accuracy.

12:10 pm Sponsored Presentation (Opportunity Available)

12:40 Session Break


1:15 Session Break


RECENT REPORT AVAILABLE FROM INSIGHT PHARMA REPORTS

Detecting the Role of Extracellular RNAs in Health and Disease

2:00 Chairperson’s RemarksLynne T. Bemis, Ph.D., University of Minnesota

»2:05 KEYNOTE PRESENTATION: Circulating Extracellular RNAs as Biomarkers

Muneesh Tewari, M.D., Ph.D., Associate Professor, Internal Medicine and Biomedical Engineering & Ray and Ruth Anderson-Laurence M. Sprague Memorial Research Professor, University of Michigan Health SystemMicroRNAs as well as other classes of RNA have been found to be present in blood and other biofluids in extracellular form and are being actively investigated as biomarkers for cancer and many other diseases. I review some of the history of this field, current knowledge about circulating microRNA biochemistry, key considerations and pitfalls to avoid in performing extracellular RNA biomarker studies, as well as the outlook for the future.

2:45 The Biology of Circulating MicroRNAs in Cardiovascular Health and DiseaseStephen Y. Chan, M.D., Ph.D., Director, Center for Pulmonary Vascular Biology and Medicine; Associate Professor of Medicine, Department of Medicine, University of Pittsburgh Medical CenterPlasma-based circulating microRNAs have attracted attention in cardiovascular medicine, relevant for the study of disease states and normal physiology. I describe our recent findings regarding the dynamic regulation and biological

actions of circulating microRNAs in aerobic exercise and in pulmonary hypertension. I discuss new technologies to detect and quantify these factors. Finally, I discuss the potential utility of circulating microRNAs as putative cardiovascular biomarkers and/or therapeutic targets.


3:30 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 Comparison of Extracellular RNA Profiles across Biofluids and Their Utility for Biomarker DevelopmentKendall Van Keuren-Jensen, Ph.D., Associate Professor, Neurogenomics, TGenExamination of RNA species from several biofluids can provide a range of information about an individual. For example, there are varying amounts of tissue-specific data and exogenous RNA species present among different biofluids. Depending on the type of disease or location of injury, the choice of biofluid may be an important consideration for biomarker development.

4:30 tRNA Fragments Join the Repertoire of Small RNAs with Potential as BiomarkersLynne T. Bemis, Ph.D., Chair, Biomedical Sciences, University of MinnesotatRNA fragments are often abundant in high-throughput studies of extracellular RNA. Initially regarded as breakdown products of mature tRNA, and thus of little consequence, they are now being studied for their regulatory function in health and disease. A review of our current understanding of the functions attributed to these fragments will be presented.

5:00 Close of Conference

Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management

Cancer diagnostics based on measuring biomarkers in tissue samples has already in the past decade provided revolutionary advances in diagnosis, prognosis, and therapy selection. A major drawback of the tissue-based approach centers on the need for invasive surgical procedures in sample collection, which in a great many instances preclude following the progression or regression of disease during therapy.

In recent years, an impressive number of cancer biomarker researchers have turned their attention to the analysis of markers present in biological fluids, which can be collected with minimal invasiveness and permit following the disease over time. This highly dynamic field has come to be called liquid biopsy. In the past few years a significant and growing number of startups and several major companies have taken up the challenge of commercializing and offering liquid biopsy products and services to the market.

These procedures, for the most part, query blood samples for information to be gleaned from circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) fragments, and extracellular vesicles (EVs). CTCs have the longest history as subjects for liquid biopsy. Indeed, one decade-old commercial product has already garnered FDA approval for in vitro diagnostic use. Circulating tumor DNA, a more recent entry on the liquid biopsy scene, is fast becoming an alternative or adjunct to CTC assays. EVs are the newest and least

developed of the three liquid biopsy sample sources, and while highly promising, their ultimate value has yet to be fully established.

This report explores the background, history and basic research of liquid biopsy covering the three sample categories that dominate liquid biopsy today: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs, also known as exosomes). This report also details the commercial aspects, market dynamics, and trends of liquid biopsy.

InsightPharmaReports.comA Division of Cambridge Healthtech Institute

Liquid Biopsy:An Emerging Market for Radically Improved Cancer Management

Kenneth Rubenstein, Ph.D.

Expert Intelligence for Better Decisions


SPONSORSHIP, EXHIBIT, AND LEAD GENERATION OPPORTUNITIES CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space, branding and networking with specific prospects. Sponsorship allows you to achieve your objectives before, during, and long after the event. Any sponsorship can be customized to meet your company’s needs and budget. Signing on early will allow you to maximize exposure to qualified decision-makers.

Podium Presentations – Available within the Main Agenda!Showcase your solutions to a guaranteed, targeted audience. Package includes a 15- or 30-minute podium presentation within the scientific agenda, exhibit space, on-site branding, access to cooperative marketing efforts by CHI, and more.

Breakfast & Luncheon Podium PresentationsOpportunity includes a 30-minute podium presentation. Boxed lunches are delivered into the main session room, which guarantees audience attendance and participation. A limited number of presentations are available for sponsorship and they will sell out quickly. Sign on early to secure your talk!

Invitation-Only VIP Dinner/Hospitality SuiteSponsors will select their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects, helping you to make the most out of this invaluable opportunity. Evening will be customized according to sponsor’s objectives i.e.:

• Purely social • Focus group• Reception style • Plated dinner with specific conversation focus

ExhibitExhibitors will enjoy facilitated networking opportunities with qualified delegates. Speak face-to-face with prospective clients and showcase your latest product, service, or solution.

One-on-One Meetings Select your top prospects from the pre-conference registration list. CHI will reach out to your prospects and arrange the meeting for you. A minimum number of meetings will be guaranteed, depending on your marketing objectives and needs. A very limited number of these packages will be sold.

Additional branding and promotional opportunities are available, including:• Conference Tote Bags• Literature Distribution (Tote Bag Insert or Chair Drop)

• Badge Lanyards • Padfolios • Program Guide Advertisement

Looking for additional ways to drive leads to your sales team? CHI’s Lead Generation Programs will help you obtain more targeted, quality leads throughout the year. We will mine our database of 800,000+ life science professionals to your specific needs. We guarantee a minimum of 100 leads jper program! Opportunities include:

• Whitepapers • Web Symposia• Custom Market Research Surveys • Podcasts

For sponsorship and exhibit information, please contact:Terry Manning, Business Development Manager 781-972-1349 | [email protected]

OFFICIAL PUBLICATION LEAD SPONSORING PUBLICATIONS SPONSORING PUBLICATIONS

WEB PARTNERS

HOTEL & TRAVEL INFORMATIONConference Venue and Hotel: Hotel Kabuki1625 Post StreetSan Francisco, CA 94115Phone: 415-922-3200

Reservations: Go to the travel page of LiquidBiopsySummit.com

Discounted Room Rate: $209 s/dDiscounted Room Rate Cut-off Date: May 26, 2016

Reservations and Additional Travel Information:Go to the travel page of LiquidBiopsySummit.com

Please refer to the Registration Code below:

How to Register: [email protected] • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use keycode CFDX F

when registering!

Pricing and Registration InformationSHORT COURSE PRICING

Academic, Government, Commercial Hospital-affiliated

Short Course Only $699 $399

Thursday, June 23 SC1: Molecular Beacons; Stellaris FISH Probes; and SuperSelective PCR Primers for Liquid Biopsies

SYMPOSIUM PRICING

Symposium Only $999 $599

Wednesday, June 22 S1: Circulating Markers in Cancer: Tools for Identification, Evaluation and Translation

CONFERENCE PRICING

STANDARD PACKAGE (Includes Symposium & Conference Program. Excludes Short Course.)Early Registration Discount until March 18, 2016 $2199 $1129Advance Registration Discount until May 13, 2016 $2349 $1179

Registrations after May 13, 2016, and on-site $2549 $1249

BASIC PACKAGE (Includes Conference Program Only. Excludes Symposium and Short Course.)Early Registration Discount until March 18, 2016 $1549 $729Advance Registration Discount until May 13, 2016 $1749 $799Registrations after May 13, 2016, and on-site $1949 $879

INSIGHT PHARMA REPORT PRICING

INSIGHT PHARMA REPORT: LIQUID BIOPSY (Order Insight Pharma Report at Special Discounted Rate)

Liquid Biopsy Report $1100 $700

CONFERENCE DISCOUNTS

Poster Submission - Discount ($50 Off): Poster abstracts are due by May 13, 2016. Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact [email protected]. *CHI reserves the right to publish your poster title and abstract in various marketing materials and products.REGISTER 3 - 4th IS FREE: Individuals must register for the same confer-ence or conference combination and submit completed registration form together for discount to apply.

Group Discounts: Discounts are available for multiple attendees from the same organization. For more information on group rates contact David Cunningham at +1-781-972-5472Alumni Discount - SAVE 20%: CHI appreciates your participation at our events. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate.

ADDITIONAL REGISTRATION DETAILSEach registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.To view our Substitutions/Cancellations Policy, go to healthtech.com/regdetailsVideo and or audio recording of any kind is prohibited onsite at all CHI events.

Reports designed to keep life science professionals informed of the salient trends in pharma technology, business, clinical development, and therapeutic disease markets InsightPharmaReports.com Contact Adriana Randall, [email protected], +1-781-972-5402.

Barnett is a recognized leader in clinical education, training, and reference guides for life science professionals involved in the drug development process. For more information, visit BarnettInternational.com.

Complimentary news delivered to your inbox

Insights on the innovation between clinical trial management and delivery of care. ClinicalInformaticsNews.com

News on the data deluge in petascale computing and the tools to deliver individualized medicine. Bio-ITWorld.com

Emerging Technologies in Diagnostics DiagnosticsWorldNews.com

Cambridge Healthtech Institute250 First Avenue, Suite 300Needham, MA 02494www.healthtech.comFax: 781-972-5425

LIQUID BIOPSY SUMMITTHEJUNE 22 - 24, 2016 HOTEL KABUKI | SAN FRANCISCO, CALIFORNIA

If you are unable to attend but would like to purchase The Liquid Biopsy Summit 2016 CD for $350 (plus shipping), please visit LiquidBiopsySummit.com. Massachusetts delivery will include sales tax.

The Liquid Biopsy Summit Brochure 2016

Health & Medicine

Transcript of The Liquid Biopsy Summit Brochure 2016